TrialThe Lancet. Haematology2019
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
163 papers cite itlatest 60 shown
this paperpooled ittrialcites it